Corona Remedies Debuts on Dalal Street with Impressive Listing at 38% Premium
Corona Remedies made a remarkable entrance on Dalal Street, debuting with a 38.42% premium over its IPO price of Rs 1,062. The shares are now available for trading on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). As of 11:11 AM, the stock was trading at Rs 1,470 on the NSE and Rs 1,473 on the BSE, reflecting a 1.45% increase.
Corona Remedies IPO Performance
The initial public offering (IPO) of Corona Remedies, valued at Rs 655 crore, was entirely structured as an offer for sale. It garnered an overwhelming response from investors, being oversubscribed 144.5 times overall. Institutional investors showed significant interest, with qualified institutional buyers subscribing nearly 294 times and non-institutional investors over 220 times. Retail investors also participated robustly, taking up their allocation more than 30 times. This high demand underscores strong confidence in the company’s business strategy, product offerings, and earnings potential. Notably, Corona Remedies did not raise new capital through the IPO; all proceeds were directed to selling shareholders. The company entered the public market with a solid balance sheet and a history of consistent profitability. Based on the IPO price, its market valuation is approximately Rs 6,495 crore, with a post-issue price-to-earnings multiple of around 35 times, calculated using annualized FY26 earnings. Despite the high valuation, investors seem willing to pay a premium for the company’s steady growth and high margins.
Financial Performance
Corona Remedies has demonstrated impressive financial growth. For the fiscal year 2025, the company reported an 18% increase in revenue, reaching Rs 1,202 crore. Additionally, profit after tax surged by 65% to Rs 149 crore. In the quarter ending June 2025, the profit after tax stood at Rs 46 crore, indicating sustained momentum into FY26. The company maintains robust return ratios, with a return on equity (ROE) of 27.5% and a return on capital employed (ROCE) exceeding 41%. This strong performance is supported by disciplined capital management and a low debt-to-equity ratio of 0.1. Prior to the IPO, anchor investors had committed nearly Rs 195 crore, which added credibility and stability to the offering. The involvement of long-only domestic and global funds in the anchor book helped establish a strong institutional demand during the public sale.
Company Overview
Founded with a focus on women’s healthcare, cardiology, pain management, urology, and other chronic therapies, Corona Remedies has built a comprehensive distribution network across 22 states in India. The company employs over 2,600 medical representatives, ensuring a wide reach for its products. This strategic focus on diverse therapeutic areas positions Corona Remedies as a key player in the healthcare sector, catering to various medical needs. The company’s commitment to quality and innovation continues to drive its growth and market presence, making it a noteworthy entrant in the public markets.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
